Triana Biomedicines Raises $120M Series B to Advance Molecular Glue Degrader Pipeline into the Clinic
Triana Biomedicines, a privately held biotechnology company based in Lexington, Massachusetts, has closed an oversubscribed $120 million Series B financing to advance its molecular glue degrader pipeline and move its lead therapeutic candidate toward clinical development. The financing represents a major milestone for the company as it transitions from preclinical research into human studies and scales its drug discovery and development operations.
The Series B round was co-led by Ascenta Capital and Bessemer Venture Partners, reflecting strong investor confidence in Triana’s scientific approach and long-term potential. New investors participating in the round included YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures. Existing investors that also took part included RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, and Surveyor Capital.
Triana plans to deploy the new capital to advance its lead program, TRI-611, a molecular glue degrader designed to target anaplastic lymphoma kinase–positive non-small cell lung cancer. The company intends to bring the candidate into clinical proof-of-concept studies while continuing to expand its broader pipeline. In parallel, Triana expects to nominate a second development candidate in 2026, leveraging its proprietary discovery platform to address additional oncology targets.
The company’s drug discovery approach is built around a target-first and proximity-first strategy that focuses on identifying small molecules capable of inducing the degradation of disease-causing proteins. Molecular glue degraders work by promoting interactions between target proteins and the cellular machinery responsible for protein breakdown, offering a way to address targets that have historically been difficult or impossible to drug with conventional modalities. Triana’s platform integrates bespoke chemical libraries, mechanistic biology, and structure-based design to systematically discover and optimize these compounds.
Leadership at Triana has emphasized that TRI-611 is intended to address resistance mechanisms that limit the effectiveness of existing therapies for ALK-positive cancers. By degrading specific ALK variants rather than inhibiting their activity, the company believes its approach may offer a differentiated therapeutic option for patients who have exhausted current treatment alternatives. The Series B funding is expected to support the manufacturing, regulatory, and operational activities required to initiate clinical studies.
As part of the financing, representatives from the lead investors have joined Triana’s board of directors, adding operational and strategic expertise as the company enters its clinical phase. The expanded board is expected to play a key role in guiding development strategy, capital allocation, and future fundraising efforts as Triana continues to scale.
The Series B round builds on Triana’s earlier financing and strategic partnerships, including a previously announced collaboration with Pfizer focused on the discovery of molecular glue degraders across multiple targets. That agreement provided non-dilutive capital and validated Triana’s platform through engagement with a major pharmaceutical partner.
Triana’s $120 million raise stands out amid continued investor interest in targeted protein degradation and next-generation oncology platforms. The participation of both venture capital firms and corporate venture arms highlights the growing belief that molecular glue degraders could expand the range of druggable targets and reshape cancer drug development.
With fresh capital in place, Triana Biomedicines is now positioned to execute on key clinical and pipeline milestones. As the company advances its lead program and broadens its portfolio, it aims to establish itself as a leading player in the rapidly evolving field of targeted protein degradation and precision oncology.
